Cidara Therapeutics, Inc.CDTXNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -100.00% | -100.00% | -100.00% | -100.00% | +0.00% |
| Gross Profit Growth | +0.00% | -100.00% | +0.00% | -100.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +44.65% | +116.57% | +212.44% | +240.67% | +138.09% |
| Weighted Average Shares Diluted Growth | +44.65% | +114.97% | +212.44% | +240.67% | +138.09% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -40.49% | -87.96% | -76.73% | -20.86% | +9.54% |
| Inventory Growth | -100.00% | -100.00% | -100.00% | +0.00% | +0.00% |
| Asset Growth | +155.77% | +220.45% | +263.70% | +208.22% | +219.50% |
| Book Value per Share Growth | +894.49% | +0.00% | +0.00% | +12.36% | +53.43% |
| Debt Growth | -9.50% | -26.68% | -42.48% | -45.74% | -49.68% |
| R&D Expense Growth | +19.67% | +205.33% | +315.61% | +272.80% | +185.86% |
| SG&A Expenses Growth | +50.50% | +1.94% | +71.83% | +37.00% | +63.12% |